Conavi Medical files prospectus for common share offering

Conavi Medical filed a preliminary prospectus for an equity offering of common shares and pre-funded warrants, with proceeds targeted for a limited U.S. market release, working capital, and general corporate purposes. The company also reported FDA clearance for its hybrid IVUS/OCT imaging system, supporting a limited U.S. commercial launch in the second half of 2026. Despite the positive product milestone, the financing appears driven by financial strain, with a current ratio of 0.6, negative free cash flow of $15 million over the last 12 months, and shares near their 52-week low of $0.26.

Analysis

This financing is less a growth signal than a survival bridge, and that matters because the market will likely underwrite the launch optionality only if dilution is kept contained. A sub-1.0 current ratio plus persistent cash burn means the equity raise likely comes at a meaningful discount, which can cap upside even if the FDA clearance is real. The immediate winner is the company’s ability to stay listed and fund a U.S. pilot, but the economic value of that launch depends on whether it can convert regulatory approval into repeatable placement economics before the balance sheet forces a second raise.

Competitive dynamics favor larger medtech platforms with existing cath lab distribution, because the limiting factor is not clearance but adoption friction. A hybrid IVUS/OCT system needs physician retraining, capital equipment acceptance, and reimbursement clarity; that creates a slow ramp and gives entrenched incumbents time to respond with bundled pricing or salesforce pressure. The second-order effect is that suppliers and channel partners tied to a successful launch could see a small near-term pull-forward, but the more important read-through is that any weak uptake would likely depress valuation across other pre-scale device names that are financing commercial launches into a tough funding tape.

The key catalyst window is the next 6-12 weeks: pricing, discount depth, and whether insiders support the deal will tell you if management is preserving optionality or simply buying time. A tight raise with warrant coverage could de-risk the story enough for a tactical bounce; a large discounted deal would likely signal that the market is assigning low probability to a self-funded U.S. rollout. The contrarian view is that the FDA clearance may be enough to re-rate the stock off distressed levels if the company can demonstrate even a handful of installed accounts, but that upside is probably nonlinear only after evidence of reimbursement or distributor traction, not on approval alone.

Key Decisions for Investors

• Avoid chasing the common equity into the financing print; wait for final pricing and warrant structure, then reassess only if dilution is modest and the raise is clearly over-subscribed.
• If liquidity is adequate, consider a tactical long only after the deal closes and the stock absorbs selling pressure; target a 4-8 week trade around post-financing stabilization, with stop loss if volume fails to normalize.
• For risk-controlled upside exposure, prefer call options or a small common position over size; the payoff is contingent on evidence of commercial traction over the next 1-2 quarters, not the FDA event itself.
• Use a pair trade: long a profitable, scaled medtech platform versus short a pre-revenue or cash-burning launch story to isolate execution risk and financing dilution risk over the next 3-6 months.
• Monitor for a second financing within 6-9 months; if the company needs to return to market quickly after the U.S. launch, the equity story becomes structurally unattractive and any rally should be faded.